by admin | Apr 4, 2022 | Insights
“Psilocybin, the active ingredient in psychedelic mushrooms, has shown promise in limited early studies, not only in alcohol and harder drugs, but also nicotine — all of which resist long term treatment.” This article in The New York Times delves into some...
by admin | Apr 4, 2022 | Insights
Emerging research makes a strong case for a future where psychedelics are a regular part of psychopharmacology. Forbes takes us through four reasons why psychedelics show immense promise in the future of mental...
by admin | Apr 4, 2022 | Insights
An update on the status of psilocybin research in North Carolina: “Basically, a single dose of these drugs has this sort of robust long lasting effect with people who have difficult-to-treat depression,” said Dr. Bryan Roth, a professor at University of North...
by admin | Apr 3, 2022 | Uncategorized
In this piece from Psychedelic Spotlight, James Hallifax covers the five most influential psychedelic medicine clinical trials of recent years. #psychedelicscience #psilocybin #psychedelicresearch #psychedelicmedicine #research Link to post Link to article...
by admin | Apr 3, 2022 | Insights
This article from 2021 provides a comprehensive primer on the steps of a clinical trial process for #psychedelic medicines in the United States. #psychedelicscience #psilocybin #psychedelicresearch #psychedelicmedicine #research Link to post Link to...
Recent Comments